Susquehanna Fundamental Investments’s Sarepta Therapeutics SRPT Stock Holding History

Susquehanna Fundamental Investments’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-65,382	Closed	-$7.49M	–	572
2023 Q2	$7.49M	Sell	65,382 -16,001	-20%	-$2.06M	0.27%	108
2023 Q1	$11.2M	Sell	81,383 -4,572	-5%	-$593K	0.26%	112
2022 Q4	$11.1M	Sell	85,955 -13,522	-14%	-$1.57M	0.19%	158
2022 Q3	$11M	Buy	+99,477	New	+$10M	0.19%	154
2022 Q1	$4.05M	Buy	51,860 +2,851	+6%	+$218K	0.08%	350
2021 Q4	$4.41M	Buy	49,009 +4,700	+11%	+$402K	0.12%	224
2021 Q3	$4.1M	Buy	+44,309	New	+$3.41M	0.08%	357
2021 Q2	–	Sell	-33,800	Closed	-$2.52M	–	1775
2021 Q1	$2.52M	Buy	+33,800	New	+$3.12M	0.04%	559

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Susquehanna Fundamental Investments's SRPT Position: Q3 2023 in Review

Susquehanna Fundamental Investments sold out of Sarepta Therapeutics (SRPT) in Q3 2023, closing a stake of 65,382 shares — an estimated $7.49M sold.

Susquehanna Fundamental Investments first reported a position in SRPT in Q1 2021 and held it in 8 quarters. The position peaked at $11.2M in Q1 2023. 395 funds tracked by Wall St. Rank hold SRPT as of Q3 2023.

Susquehanna Fundamental Investments reported no remaining Sarepta Therapeutics position as of Q3 2023 after selling out during the quarter.
Susquehanna Fundamental Investments sold 65,382 Sarepta Therapeutics shares in Q3 2023, an estimated $7.49M.
Susquehanna Fundamental Investments first reported a position in Sarepta Therapeutics in Q1 2021 and held it in 8 quarters.
Susquehanna Fundamental Investments's Sarepta Therapeutics position peaked at $11.2M in Q1 2023.
395 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2023.

Based on Susquehanna Fundamental Investments's 13F filing for Q3 2023, filed 14 Nov 2023.